1Department of Cardiology, Division of Electrophysiology, University Heart Center Zurich,
Switzerland; 2Age-Related Health Care, Tallaght University Hospital/Department of …

The current manuscript is the second update of the original Practical Guide, published in
2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …

Objective To compare the efficacy, safety, and cost effectiveness of direct acting oral
anticoagulants (DOACs) for patients with atrial fibrillation. Design Systematic review …

The current manuscript is an update of the original Practical Guide, published in June 2013
[Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart …

New oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to
prevent stroke in patients with non-valvular atrial fibrillation (AF). Both physicians and …

Atrial fibrillation (AF) confers a substantial risk of mortality and morbidity from stroke and
thrombo-embolism, and this common cardiac arrhythmia represents a major healthcare …

ESC Guidelines 2721 the outcome of disease may be favourably influenced by the thorough
application of clinical recommendations. Thus, the task of writing guidelines covers not only …

Contemporary medicine is shifting towards person rather than disease-oriented care. 1 With
increasing life expectancy and the ageing of baby boomers, the proportion over 60 years is …

Рекомендации разработаны экспертами Российского кардиологического общества в
сотрудничестве с Всероссийским научным обществом специалистов по клинической …

Background Three novel direct oral anticoagulants (DOACs) have recently been registered
by the Food and Drug Administration and European Medicines Agency Commission …